Isosorbide-5-Mononitrate shortage — CA supply status & alternatives

Isosorbide-5-Mononitrate

—

In supply · Australia

Pms-Ismn

In supply · 🇦🇺 Australia · short in🇨🇦 CA🇮🇹 IT🇳🇿 NZ

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Isosorbide-5-Mononitrate

Brand names	Pms-Ismn

Therapeutic category	Auto-created by Health Canada — Drug Shortages Database scraper

Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Global API supply base 🇺🇸 FDA Drug Master Files · active Type II

1 API manufacturer

Manufacturers with an active Type II Drug Master File — i.e. cleared to supply this active ingredient into the US market. A proxy for how concentrated the global manufacturing base is.

Very high concentration risk

Dipharma Francis Srl

Manufacturing countries: Italy · Source: FDA List of Drug Master Files

Verified timeline regulator events

🇮🇹 1 Sept 2026

Shortage resolved

🇮🇹 30 June 2026

medium reported

🇮🇹 1 June 2026

Shortage resolved

🇮🇹 11 May 2026

medium reported

🇳🇿 29 Apr 2026

high reported

🇳🇿 9 Apr 2026

high reported

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.